ArticleParasitology research2025
Serological determination of Trypanosoma cruzi in northern region of the State of Mexico.
Article in Parasitology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transmission risk of Trypanosoma cruzi through blood donors in a third-level care hospital.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease, caused by Trypanosoma cruzi, remains a significant public health problem in Mexico, particularly challenging to diagnose during its chronic phase, due to low parasitemia and the complex immune response. According to the Pan American Health Organization, no single test is sufficiently sensitive or specific to reliably detect chronic Chagas disease, requiring the use of multiple serological methods when results are inconclusive. This study aimed to assess the seroprevalence of Chagas disease in the largely uncharted municipalities of the North of State of Mexico. A total of 250 serum samples from 17 municipalities were analyzed using a comprehensive approach involving three serological tests: the BIO-CHAGAS commercial kit (MEXLAB®), an ELISA test with antigens derived from an endemic strain, and a confirmatory Western blot analysis. The results revealed that 240 samples were negative, 3 were inconclusive, and 7 were positive, yielding a seroprevalence rate of 2.8% (7/250). The endemicity demonstrated in the municipalities of Hueypoxtla and Tequixquiac, combined with the documented presence of the vector Triatoma barberi in these areas, suggests an ongoing risk of T. cruzi transmission. These findings underscore the urgent need for targeted public health interventions, including increased surveillance, community awareness, vector control programs, screening tests to identify cases, and prompt treatment, to curb the spread of Chagas disease in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.